Showing 391-400 of 450 results for "".
- Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments Intraocular Dyeshttps://modernod.com/news/bausch-lomb-named-exclusive-global-distributor-of-alfa-instruments-intraocular-dyes/2481060/Bausch + Lomb and Alfa Instruments announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments' line of surgical intraocular dyes—Vitreocare—globally with the exception of Italy, wh
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- I-Med Pharma USA Partners With DryEye Rescue to Distribute Its Dry Eye Product Portfolio in the United Stateshttps://modernod.com/news/i-med-pharma-usa-partners-with-dryeye-rescue-to-distribute-its-dry-eye-product-portfolio-in-the-united-states/2480614/With the recent launch of its line of dry eye diagnostics, management, and treatment solutions into the United States, I-MED Pharma USA has partnered with DryEye Rescue of Boca Raton, Florida to distribute and market their dry eye product portfolio. DryEye Rescue will help raise awareness of
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial-2/2479337/Nicox SA announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase, as well as the required two-week, follow-up period. Top-line results are expected to be announced in September 2021. “The Phase 2b Missis
- Novaliq Announces More Than Half of Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2https://modernod.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/Novaliq announced today that the second Phase 3 clinical trial evaluating CyclASol to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the second half of 2021. The Phase 3 program for CyclASol
- After the American Academy of Ophthalmology’s Urging, Blue Cross Blue Shield Clarifies Eylea Policyhttps://modernod.com/news/after-the-american-academy-of-ophthalmologys-urging-blue-cross-blue-shield-clarifies-eylea-policy/2478988/Blue Cross Blue Shield informed the American Academy of Ophthalmology (AAO) of their updated policy on Eylea treatment to allow for continued coverage of patients who have lost three lines of vision on an eye chart, according to an AAO news release. The American Academy of Ophthalmology ha
- Rayner Launches Raytrace Premium IOL Calculator Update to Include Posterior Corneal Astigmatismhttps://modernod.com/news/rayner-launches-raytrace-premium-iol-calculator-update-to-include-posterior-corneal-astigmatism/2478444/Rayner announced the launch of their updated web-based premium IOL calculator, Raytrace. Developed in line with surgeon feedback, the new Raytrace version 3.5 includes the following improvements: Inclusion of Posterior Corneal Astigmatism (PCA) for more accurate toric IOL calculation
- CooperVision Recaps Complimentary Contact Lens Program for Essential Hospital Workershttps://modernod.com/news/coopervision-recaps-complimentary-contact-lens-program-for-essential-hospital-workers/2478307/Over the past 4 months, CooperVision’s Essential Hospital Workers Complimentary Contact Lens Program enabled eye care professionals to provide support to patients working on the front lines of the COVID-19 pandemic. By the program’s conclusion on August 31, nearly 570 optometry practices from 46
- BVI Introduces Patient Packs Aimed at Helping US Ophthalmologists Bring Patients Backhttps://modernod.com/news/bvi-introduces-patient-packs-aimed-at-helping-us-ophthalmologists-bring-patients-back/2478280/BVI has released a line of Patient Packs to help US ophthalmologists bring patients back to the office and OR with confidence, according to a company news release. Ophthalmologists are seeking to get back to normal and address the backlog of patients whose vision has been negatively impact